Listen now (22 min) | Founded in 2016, South Rampart Pharma is a clinical-stage life science company dedicated to advancing the safe treatment of pain by developing new non-opioid small molecule solutions that lack the liver and kidney toxicity present in current pain medicines. The company's lead program, SRP-001, is currently in a Phase 1 study evaluating the safety, tolerability, and pharmacokinetics with data expected later this year in 2023.